Showing 4341-4350 of 6036 results for "".
- Neurophth Announces First Patient Dosed in Phase 1/2 Clinical Trial of Second Gene Therapyhttps://modernod.com/news/neurophth-announces-first-patient-dosed-in-phase-12-clinical-trial-of-second-gene-therapy/2481786/Neurophth Therapeutics announced that the first patient has been dosed in the international multi-region, multicenter phase 1/2 clinical trial for the treatment of Leber hereditary optic neuropathy caused by ND1 mutation (ND1-LHON). Neurophth is conducting a phase 1/2, mu
- Amber Ophthalmics Announces First Patient Enrolled in Phase 2/3 Trial Evaluating Nexagon for the Treatment of PCEDhttps://modernod.com/news/amber-ophthalmics-announces-first-patient-enrolled-in-phase-23-trial-evaluating-nexagon-for-the-treatment-of-pced/2481785/Amber Ophthalmics announced that Mark S. Gorovoy, MD, has enrolled the first patient in the AMB-01-006 (NEXPEDE-1), a randomized, double-masked, vehicle-controlled phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon (lufepirsen ophthalmic gel) for
- ViGeneron Announces EMA Approval of Clinical Trial Application for VG901, a Gene Therapy to Treat RPhttps://modernod.com/news/vigeneron-announces-ema-approval-of-clinical-trial-application-for-vg901-a-gene-therapy-to-treat-retinitis-pigmentosa/2481784/ViGeneron announced that the European Medicines Agency (EMA) has approved the clinical trial application for VG901, a gene therapy to treat CNGA1-associated retinitis pigmentosa (RP). VG901 uses vgAAV, ViGeneron's proprietary adeno-associated virus (AAV) vector to deliver the CNGA1
- FDA Approves Regeneron's High-Dose Aflibercept, Eylea HDhttps://modernod.com/news/fda-approves-regenerons-high-dose-aflibercept-eylea-hd/2481782/In a major move that is expected to significantly extend dosing intervals for patients with retinal diseases, Regeneron received FDA approval for Eylea HD (aflibercept 8 mg) for patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic reti
- Sandoz Announces Results from Mylight Phase 3 Study for Biosimilar Aflibercepthttps://modernod.com/news/sandoz-announces-results-from-mylight-phase-3-study-for-biosimilar-aflibercept/2481777/Sandoz released positive results from the MYLIGHT phase 3 confirmatory efficacy and safety study for its biosimilar aflibercept for wet macular degeneration (AMD). The Mylight phase 3 confirmatory efficacy and safety study (ClinicalTrials.gov NCT04864834) met its pri
- Lineage Cell Therapeutics Provides Update on OpRegenhttps://modernod.com/news/lineage-cell-therapeutics-provides-update-on-opregen/2481775/Lineage Cell Therapeutics provided an update on its progress with OpRegen (RG6501), its product candidate for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Lineage stated that it continues to execute its
- Rayner Completes First Implantations of IOLs in Clinical Trials in China and the UShttps://modernod.com/news/rayner-achieves-milestone-implantations-in-clinical-trials-in-china-and-the-us/2481774/Rayner has announced the completion of the first implantations in two pivotal market access studies in the US and China. Rayner's RayOne EMV Toric IOL received investigational device exemption (IDE) approval from the FDA in June. The first study implantation took place at
- Regeneron Presents 2-Year PULSAR Trial Results for Aflibercept 8 MG in Wet AMDhttps://modernod.com/news/regeneron-presents-2-year-pulsar-trial-results-for-aflibercept-8-mg-in-wet-amd/2481772/Regeneron announced positive, 2-year (96 weeks), topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration (AMD). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing interv
- Oculis Announces that OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Primary Endpoints in Phase 3 OPTIMIZE Trialhttps://modernod.com/news/oculis-announces-that-ocs-01-first-investigational-eye-drop-for-front-and-back-of-the-eye-met-primary-endpoints-in-phase-3-optimize-trial/2481769/Oculis announced positive topline results from its phase 3 OPTIMIZE trial with OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical Optireach formulation of dexamethasone for the treatment of inflammation and pain following ocular surgery. OPTI
- Haag-Streit to Host ‘Eyestar 900 Pearls of Cataract & Refractive Surgery with Swept-Source OCT’ Satellite Symposiumhttps://modernod.com/news/haag-streit-to-host-eyestar-900-pearls-of-cataract-refractive-surgery-with-swept-source-oct-satellite-symposium/2481767/Haag-Streit announced it will host the ‘Eyestar 900 Pearls of Cataract & Refractive Surgery with Swept-Source OCT’ Satellite Symposium at the 41st Congress of the ESCRS in September. Haag-Streit invites delegates to join its distinguished faculty for